Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. eyetreat

EyeTREAT SIGNED

Innovative tool for personalized treatment of patients with neovascular age-macular degeneration: dosage optimization for long term efficacy treatment

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 EyeTREAT project word cloud

Explore the words cloud of the EyeTREAT project. It provides you a very rough idea of what is the project "EyeTREAT" about.

models    patient    tools    definitely    candidate    reducing    eye    efficient    visual    rest    retina    scan    combining    threatening    pioneer    inter    europeans    expertise    clinical    tool    instance    centre    anticipated    consists    ball    degeneration    optical    benefit    life    anti    dosing    clear    intervals    pharmacokinetic    university    almost    technique    care    health    2040    amd    ocular    dose    missing    first    vegf    patients    burden    regular    with    appropriate    manchester    lucentis    measuring    disciplinary    eylea    linking    lasting    injection    renowned    25    character    frequency    determinations    vitreous    avastin    imaging    sectoral    computational    regimen    effect    intravitreal    injections    researcher    consensus    tomography    population    coherence    ophthalmic    treatment    million    drug    quality    optimization    thickness    constitute    oct    personalization    clinics    varies    invasively    quantitative    career    macular    individual    ageing    age    pharmacodynamic    central    individualized    illnesses    therapeutic    treatments   

Project "EyeTREAT" data sheet

The following table provides information about the project.

Coordinator		 THE UNIVERSITY OF MANCHESTER 

Organization address
address: OXFORD ROAD
city: MANCHESTER
postcode: M13 9PL
website: www.manchester.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country United Kingdom [UK]
 Project website https://www.research.manchester.ac.uk/portal/evamaria.delamo.html
 Total cost 122˙159 €
 EC max contribution 122˙159 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2018
 Duration (year-month-day) from 2018-09-01   to  2019-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THE UNIVERSITY OF MANCHESTER UK (MANCHESTER) coordinator 122˙159.00

Map

 Project objective

With the ageing population, visual threatening illnesses are increasing. For instance, age-related macular degeneration (AMD) is expected to affect almost 25 million Europeans by 2040. The AMD treatment consists in regular injections of the anti-VEGF therapeutic drug (Lucentis, Avastin, Eylea) into the eye ball, vitreous, for the rest of the patient life. However, the dosing intervals varies widely among the patients and there is no a clear consensus or quantitative method for evaluating the injection frequency. For that, computational tools linking the drug dose regimen and the drug effect in the retina are needed. However, such pharmacokinetic-pharmacodynamic models are still missing. Combining population pharmacokinetic and optical coherence tomography (OCT) imaging technique is a new, novel and promising approach. The drug effect can be evaluated non-invasively, measuring the central macular thickness in the retina scan. The models generated will allow appropriate individualized dosing regimen to the patients in clinics that will be anticipated from individual retina scan determinations with OCT. The optimization and personalization of dosing regimen will ensure an efficient long-lasting treatment, improving patient quality of life while reducing the burden to the health care system. Moreover, the models will increase our understanding in the treatments, constitute a pioneer tool in effect assessment in ocular therapeutic field and a first step towards more advanced ophthalmic models. The candidate has strong expertise in intravitreal pharmacokinetic and this project will advance her into clinical pharmacodynamic modelling at the renowned Centre for Applied Pharmacokinetic Research, University of Manchester. The inter-disciplinary and inter-sectoral character of the project will definitely benefit her career development as a researcher.

 Publications

year authors and title journal last update
List of publications.
2019 Astrid Subrizi, Eva M. del Amo, Viktor Korzhikov-Vlakh, Tatiana Tennikova, Marika Ruponen, Arto Urtti
Design principles of ocular drug delivery systems: importance of drug payload, release rate, and material properties
published pages: 1446-1457, ISSN: 1359-6446, DOI: 10.1016/j.drudis.2019.02.001 		Drug Discovery Today 24/8 2020-04-11

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EYETREAT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EYETREAT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

MathematicsAnalogies (2019)

Mathematics Analogies

Read More  

NaWaTL (2020)

Narrative, Writing, and the Teotihuacan Language: Exploring Language History Through Phylogenetics, Epigraphy and Iconography

Read More  

MingleIFT (2020)

Multi-color and single-molecule fluorescence imaging of intraflagellar transport in the phasmid chemosensory cilia of C. Elegans

Read More